ArticleBMJ open2026
Evaluating the effectiveness and safety of adjuvant transcatheter arterial chemoembolisation (TACE) after curative resection for Barcelona Clinic Liver Cancer (BCLC) stage 0-B hepatocellular carcinoma: protocol for a target trial emulation study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAccording to Chinese clinical practice guidelines, patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative hepatectomy should have adjuvant transcatheter arterial chemoembolisation (TACE). However, the National Comprehensive Cancer Network and the European Association for the Study of the Liver guidelines take a more conservative stance on the routine use of adjuvant TACE. A recent randomised controlled trial (RCT) found no benefit of adjuvant TACE for patients with early-stage HCC. Given the potential ethical concerns, it is impractical to conduct another RCT. Therefore, we plan to use a target trial emulation (TTE) framework to estimate the effectiveness and safety of adjuvant TACE in patients with resectable HCC, classified as Barcelona Clinic Liver Cancer stage 0-B, with subgroup analyses to identify potential effect-modifying subpopulations. METHOD AND ANALYSIS: A TTE framework using the cloning-censoring-weighting approach with a 4-week grace period will be implemented. Eligible patients will be cloned into the adjuvant TACE and active surveillance groups and artificially censored on deviation from their assigned treatment strategy. Potential confounders will be identified using a directed acyclic graph and inverse probability of censoring weights will be applied to adjust for bias arising from artificial censoring. Subgroup analyses will be prespecified based on the potential sources of treatment-effect heterogeneity. ETHICS AND DISSEMINATION: The institutional review board of West China Hospital, Sichuan University, approved this study (Approval No. 2025(1790)). Given the study's retrospective design and the use of de-identified data, informed consent was waived. The results of this research will be disseminated through publication in a peer-reviewed journal and presentation at scientific conferences. TRIAL REGISTRATION NUMBER: ChiCTR2600121012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.